Early market access of cancer drugs in the EU

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 96-105

  Martinalbo, J ^a   Bowen, D ^a   Camarero, J ^b   Chapelin, M ^a   Demolis P ^c   Foggi, P ^d   Jonsson, B ^e   Llinares, J ^a   Moreau, A ^c   O'Connor, D ^f   Oliveira, J ^g   Vamvakas, S ^a   Pignatti, Francesco ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b Department of Medicines for Veterinary Use   (Spain)

^c French National Agency for Medicines and Health Products Safety (ANSM)   (France)

^d ITALIAN MEDICINES AGENCY   (Italy)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

^f MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^g INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

Accelerated approval; Adaptive pathways; Conditional approval; Early access; HTA

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BELINOSTAT; BLINATUMOMAB; BOSUTINIB; BRENTUXIMAB VEDOTIN; CERITINIB; CRIZOTINIB; DABRAFENIB; EVEROLIMUS; IBRUTINIB; IDELALISIB; LAPATINIB; NIVOLUMAB; OBINUTUZUMAB; OFATUMUMAB; OLAPARIB; PANITUMUMAB; PAZOPANIB; PEMBROLIZUMAB; PIXANTRONE; POMALIDOMIDE; RADIUM CHLORIDE RA 223; RAMUCIRUMAB; SUNITINIB; TRAMETINIB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VANDETANIB; VISMODEGIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; EUROPE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THYROID CANCER; EUROPEAN UNION; HEALTH CARE DELIVERY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; EUROPEAN UNION; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS;

EID: 84960111620     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv506     Document Type: Article

References (54)

1. Pignatti F, Gravanis I, Herold R et al. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation. Clin Cancer Res 2011; 17: 5220-5225.
2. European Medicines Agency. Guideline on the Evaluation of Anticancer Medicinal Products in Man (EMA/CHMP/205/95/Rev.4).
3. Light DW, Lexchin J. Why do cancer drugs get such an easy ride? BMJ 2015; 350: h2068.
4. Eichler H-G, Pignatti F, Flamion B et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008; 7: 818-826.
5. Eichler HG, Abadie E, Breckenridge A et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 2011; 10: 495-506.
6. Carpenter D, Ting MM. Essay: the political logic of regulatory error. Nat Rev Drug Discov 2005; 4: 819-823.
7. Ellis LM, Bernstein DS, Voest EE et al. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014; 32: 1277-1280.
8. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum pretium-the just price. J Clin Oncol 2013; 31: 3600-3604.
9. Amir E, Seruga B, Martinez-Lopez J et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011; 29: 2543-2549.
10. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
11. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the Market for Anticancer Drugs. J Econ Perspect 2015; 29: 139-162.
12. Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 2011; 9: 208-214.
13. Woodcock J. Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther 2012; 91: 378-380.
14. Chabner B. Early accelerated approval for highly targeted cancer drugs. N EnglJ Med 2011; 364: 1087-1089.
15. Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res 2013; 19: 4305-4308.
16. Pignatti F, Jonsson B, Blumenthal G, Justice R. Assessment of benefits and risks in development of targeted therapies for cancer-the view of regulatory authorities. Mol Oncol 2015; 9: 1034-1041.
17. Miller FG, Joffe S. Balancing access and evaluation in the approval of new cancer drugs. JAMA 2011; 305: 2345-2346.
18. Joffe S, Miller FG. Equipoise: asking the right questions for clinical trial design. Nat Rev Clin Oncol 2012; 9: 230-235.
19. Guidance for Industry on Expedited Programs for Serious Conditions-Drugs and Biologics. 2014.
20. Sherman RE, Li J, Shapley S et al. Expediting drug development-the FDA's new 'breakthrough therapy' designation. N Engl J Med 2013; 369: 1877-1880.
21. Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council. http:// ec.europa.eu/health/files/eudralex/vol-1/reg_2006_507/reg_2006_507_en.pdf (4 November 2015, date last accessed).
22. European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement commission regulation (EC) no 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of regulation (EC) no 726/2004 (EMEA/509951/2006).
23. Hoekman JDB, Marie L, Boon Wouter PC. Improving the EU system for the marketing authorisation of medicines. Learning from regulatory practice. Leiden, Netherlands: Escher - The TI Pharma Platform for Regulatory Innovation, 2014.
24. Schilsky RL. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol 2003; 21: 3718-3720.
25. Willyard C. FDA's post-approval studies continue to suffer delays and setbacks. Nat Med 2014; 20: 1224-1225.
26. Johnson JR, Ning YM, Farrell A et al. Accelerated approval of oncology products: the Food and Drug Administration experience. J Natl Cancer Inst 2011; 103: 636-644.
27. Finkelstein JB. Accelerated approval regulations may need overhaul, panel suggests. J Natl Cancer Inst 2005; 97: 1802-1804.
28. Carpenter D. Can expedited FDA drug approval without expedited follow-up be trusted? JAMA Int Med 2014; 174: 95-97.
29. Banzi R, Gerardi C, Garattini S. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med 2015; 26: 572-584.
30. Boon WPC, Moors EHM, Meijer A, Schellekens H. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther 2010; 88: 848-853.
31. Arnardottir AH, Haaijer-Ruskamp FM, Straus SM et al. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 2011; 72: 490-499.
32. Richey EA, Lyons EA, Nebeker JR et al. Accelerated approval of cancer drugs:improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009; 27: 4398-4405.
33. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008; 358: 1354-1361.
34. Horning SJ, Haber DA, Selig WKD et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013; 19: 4297-4304.
35. Wilson WH, Schenkein DP, Jernigan CL et al. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res 2013; 19: 2804-2809.
36. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Health Affairs 2011; 30: 1375-1381.
37. European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to article 14(9) of Regulation (EC) No 726/2004 (EMA/ CHMP/697051/2014-Rev.1).
38. European Medicines Agency. Draft guideline on the role of pathological complete response as an endpoint in neoadjuvant breast cancer studies (EMA/CHMP/ 151853/2014).
39. Draft guideline on the use of minimal residual disease as an endpoint in chronic lymphocytic leukaemia studies (EMA/629967/2014).
40. Jonsson B, Bergh J. Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol 2012; 9: 236-243.
41. Kleijnen S, George E, Goulden S et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value Health 2012; 15: 954-960.
42. Kristensen FB, Mäkelä M, Neikter SA et al. European network for Health Technology Assessment, EUnetHTA: planning, development, and implementation of a sustainable European network for Health Technology Assessment. Int J Technol Assessment Health Care 2009; 25: 107-116.
43. Kleijnen S, Goettsch W, d'Andon A et al. EUnetHTA JA WP5: relative effectiveness assessment (REA) of pharmaceuticals. Draft background review, 2011.
44. Urbinati D, Masetti L, Toumi M. Early Access Programmes (EAPS): review of European system. In Poster PHP147, ISPOR 15th Annual European Congress, Berlin, Germany, 2012.
45. European Medicines Agency. Guideline on compassionate use of medicinal products, pursuant to Article 83 of Regulation (EC) No 726/2004 (EMEA/27170/2006).
46. Emmerich J, Dumarcet N, Lorence A. France's new framework for regulating offlabel drug use. N Engl J Med 2012; 367: 1279-1281.
47. Degrassat-Théas A, Paubel P, de Curzon OP et al. Temporary authorization for use:does the French patient access programme for unlicensed medicines impact market access after formal licensing? PharmacoEconomics 2013; 31: 335-343.
48. Green AK, Reeder-Hayes KE, Corty RW et al. The project data sphere initiative:accelerating cancer research by sharing data. Oncologist 2015; 20: 464-e20.
49. Eichler HG, Baird L, Barker R et al. From adaptive licensing to adaptive pathways:Delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 2015; 97: 234-246.
50. Baird LG, Banken R, Eichler H-G et al. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther 2014; 96: 559-571.
51. Ellenberg SS. Accelerated approval of oncology drugs: can we do better? J Natl Cancer Inst 2011; 103: 616-617.
52. Lanthier ML, Sridhara R, Johnson JR et al. Accelerated approval and oncology drug development timelines. J Clin Oncol 2010; 28: e226-e227.
53. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
54. Schnipper LE, Davidson NE, Wollins DS et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015; 33: 2563-2567.